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Concussion is a complex, heterogeneous process affecting the brain. Accurate assess-
ment and diagnosis and appropriate management of concussion are essential to ensure 
that athletes do not prematurely return to play or others to work or active military duty, 
risking re-injury. To date, clinical diagnosis relies primarily on evaluating subjects for 
functional impairment using instruments that include neurocognitive testing, subjective 
symptom report, and neurobehavioral assessments, such as balance and vestibular-oc-
ular reflex testing. Structural biomarkers, defined as advanced neuroimaging techniques 
and biomarkers assessing neurotoxicity and immunoexcitotoxicity, may complement 
the use of functional biomarkers. We hypothesize that neurotoxicity AMPA, NMDA, and 
kainite receptor biomarkers might be utilized as a part of comprehensive approach to 
concussion evaluations, with the goal of increasing diagnostic accuracy and facilitating 
treatment planning and prognostic assessment.
Keywords: concussion, mild tBi, neuropsychological evaluations, advanced Mri sequences, neurotoxicity and 
neuroplasticity biomarkers
introdUCtion
Concussion is a heterogeneous injury that requires a multifaceted and comprehensive approach for 
assessment, diagnosis, and management. Several clinical tools are routinely used, including symp-
tom report, neurocognitive testing, and postural stability/vestibular and oculomotor assessments 
(1). However, these tools, which represent functional biomarkers, have practical limitations and may 
not possess adequate sensitivity in diagnosing all concussions. More objective means of assessment, 
including advanced neuroimaging techniques and neurotoxicity biomarkers, have gained research 
attention. These may facilitate diagnosis and could potentially assist with monitoring recovery 
and determining prognosis. Preliminary studies suggest neurotoxicity biomarkers, in conjunction 
with neurocognitive testing, might improve diagnostic certainty of suspected concussions and may 
provide valuable information on what domains of brain function are affected (e.g., vestibular system) 
or the severity of a concussion (2). This may be particularly valuable, since the grading scales for 
concussion severity are not scientifically validated, lack prognostic utility, and are largely considered 
antiquated or outdated (3).
taBLe 1 | Biomechanical attempts to assess severity of concussion.
severity Characteristics transitory disturbances reference
impact force in gravity force (g) and  
radian per seconds (rad/s2)
impact location Frequent symptoms symptom 
duration
Mild direct impact
Frontal, parietal, and temporal lobes Often no symptoms, no 
functional changes
About 24 h (14)Linear acceleration ~30–65 g
Time ~ 1 ms
Brainstem, spinal tractRotational acceleration – 4,000–5,000 rad/s2 (15)
Coup-countercoup (AISa = 1)
Frontal lobe and upper end of 
brainstem
(16)
linear acceleration ~ 50–100 g
ICPb < 173 kPa
Moderate direct impact
Frontal, parietal, and temporal lobes No outward symptoms 
but substantial functional 
alterations
1–3 days (17)Linear acceleration ~70–90 g
Time ~ 1–3 ms
Rotational acceleration – 5,000–6,500 rad/s2 Brainstem, spinal tract (10)
Coup-countercoup (AIS = 2)
Frontal lobe and upper end of 
brainstem
(18)linear acceleration ~ 100–150 g
ICP ~ 140–190 kPa
Severe direct impact
Frontal, parietal, and temporal lobes Often but not always clinically 
observed functional impairment 
Up to 2–3 weeks (19)Linear acceleration >100 g
Time – 4 ms
Rotational acceleration ~ 7,000–13,000 rad/s2 Brainstem, spinal tract (20)
Coup-countercoup (AIS = 3–4)
Frontal lobe and upper end of 
brainstem
Linear acceleration ~ 150–250 g
ICP ~ 201–282 kPa
aAIS – Abbreviated Injury Scale.
bICP – intracranial pressure.
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Laboratory chemistry tests confirm systemic changes of energy 
metabolites in concussion (e.g., ATP, creatine, lactate, as well as 
blood gases and minerals) (4). Quantitative values of brain-borne 
neurotoxicity degradation fragments of ionotropic glutamate 
receptors (GluRs) and antibodies to excitotoxicity biomarkers 
in blood are important early markers of injury (5). Therefore, 
these biomarkers, when added to a comprehensive evaluation of 
concussion, may improve diagnosis and prognosis. The purpose 
of this review is to highlight the potential role of neurotoxicity 
biomarkers in a comprehensive evaluation of sports-related 
concussion.
CLiniCaL deFinitions: ConCUssion
Concussion is defined as a “complex pathophysiological process 
affecting the brain, induced by biomechanical forces,” with asso-
ciated traumatically induced alteration in mental status with or 
without loss of consciousness, as specified in a recent consensus 
statement on concussion in sports (6). Several physical, cognitive, 
emotional, somatic, and sleep-related symptoms may be present 
for days to weeks following injury. These are linked to cognitive, 
vestibular, and oculomotor dysfunction of various brain systems 
or domains (6). The terms “concussion” and “mild traumatic brain 
injury” (mTBI) are proposed to be used interchangeably, since 
much of the clinical symptomology overlaps and as many as 80% 
of concussions are diagnosed as mTBI. Neither mTBI nor concus-
sive injuries show gross abnormalities on standard neuroimaging, 
and most patients recover without permanent impairment (7, 
8). Typically, about 80% of post-concussive symptoms resolve 
spontaneously within 7–10 days of the acute phase (6).
BioMeCHaniCs oF inJUry
Rotational forces can cause a transient disruption of function 
in the reticular activating system, resulting in the loss of con-
sciousness associated with concussion (9). Prior biomechanical 
data have demonstrated that a simple impact of the head with 
a solid surface (rotational acceleration >5,000 rad/s2) leads to 
the greatest stress–strain to the frontotemporal regions, con-
necting limbic structures as well as the corpus callosum and 
cortical–spinal tract (10). As a result, rotational acceleration, 
diffuse shear, and strain forces cause variable degrees of injury 
to neurons, glia, the blood–brain barrier (BBB), and vascular 
structures, leading to transitory ionic functional disturbances 
with clinical manifestations. These include sudden confusion, 
lack of balance or coordination, vision abnormalities, and 
memory impairment (11). Despite using advanced techniques, 
such as the head impact telemetry system (HITS), researchers 
have not been able to diagnose concussion reliably by quantify-
ing a specific threshold (12). Researchers argue that the validity 
of head impact metrics has not been adequately addressed for 
sports, and clinicians have been cautioned to not rely on impact 
magnitude or location to predict acute clinical outcomes, symp-
tom severity (Table 1), neuropsychological function, or balance 
abnormalities (10, 13).
FUnCtionaL BioMarKers: CLiniCaL 
assessMent
Clinical assessment of concussion is structured around the 
various domain-specific impairments exhibited following 
taBLe 2 | test battery for concussion assessment.
tools intended use properties Limitations reference
sideline
Sports concussion 
assessment tool (SCAT3)
Sideline assessment 
diagnostic
Sensitivity 80–94% Should not be used for return to play decisions (21)
Specificity 76–91%
Computerized neurocognitive tests
Immediate post-concussion 
and cognitive testing 
(ImPACT)
In office, diagnosis 
and management
Sensitivity 82–91% Must have a trained professional for interpretation; 
potential for misuse (e.g., poor control on 
environment, use as a standalone measure)
(22, 23) http://www.
impacttest.com/
Specificity 69–89%
Test–retest reliability 
0.25–0.85
Automated Neurocognitive 
Assessment Metrics (ANAM)
In office, diagnosis 
and management
Test–retest reliability 
0.14–0.81
(24) http://www.
vistalifesciences.com/
index.php/anam-intro.html
Axon Sports Computerized 
Cognitive Assessment Tool
In office, diagnosis 
and management
Test–retest reliability 0-0.94 
(53% of ICC’s failing minimum 
standards)
www.axonsports.com/
Concussion Vital Signs In office, diagnosis 
and management
Test–retest reliability 
0.07–0.87
http://www.
concussionvitalsigns.com/
postural stability/Vestibular 
Balance error scoring system 
(BESS)
Sideline/Acute Specificity up to 91% Practice effects, poor intra/inter/after season 
reliability
(25, 26)
Sensitivity 34–64%
Sensory organization test 
(SOT)
In office Sensitivity 48–61% (27)
Specificity of 85–90%
Vestibular/oculomotor 
screening test (VOR, VMS)
In office Relies heavily on symptom report (28)
oculomotor tests
Eye-Track Advance (ETA) Sideline assessment Sensitivity 54–77% Depends on past medical history, medications, 
and drugs used 
(29)
Specificity of 67–92%
King–Devick (K–D) test Sideline Test–retest reliability 0.90 Practice effects, requires baseline (30)
Vestibular/oculomotor 
screening test (saccades, 
near point convergence)
In office Internal consistency  
(Cronbach’s alpha = 0.92)
Relies heavily on symptom report (28)
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injury – cognitive, vestibular, somatic, and emotional – adapted 
for various settings, such as on the “sideline” at sporting events 
as well as during recovery following acute, subacute, and chronic 
injury (Table 2).
sideline assessment
The Standardized Concussion Assessment Tool and its revisions 
(SCAT2, SCAT3) are the most widely used tools on the sideline 
(31). These comprise a number of empirically validated measures 
adapted across several domains of assessment, including symptom 
report, mental status, attention/memory, and balance. The SCAT 
is “likely to identify the presence of concussion in the early stages 
of post-injury,” according to the 2013 American Academy of 
Neurology concussion guidelines (32). Others argue that this tool 
is insensitive to identifying mild deficits, and is subject to practice 
effects (33). Furthermore, it should not be relied on for decisions 
regarding whether an athlete should be allowed to return to play 
(34). The Display Enhanced Testing for Concussions and mTBI 
(DETECT) system has been developed in response to the need 
for a fast and efficient sideline neuropsychological test (35). It is 
a 7-min battery of tests that allows for real-time cognitive testing 
in  situations previously deemed impractical or unavailable for 
patients with concussion, such as the sideline. However, it is still 
being examined for validity and reliability.
neurocognitive testing
Neurocognitive testing has been coined a “cornerstone” of con-
cussion management since the initial Concussion in Sport Group 
meeting in 2001. Typically, neurocognitive testing is completed 
in an office or quiet setting, and has been shown to be sensitive 
both to acute deficits (e.g., <24 h following injury) as well as those 
detected after an athlete is symptom free (36, 37). Of all the com-
mercially available computerized test batteries, the Immediate 
Post-concussion and Cognitive Testing Test Battery (ImPACT) 
is the most widely used and researched and the only one for-
mally approved by the FDA; others are summarized in Table 2. 
Although largely reserved for those with protracted recoveries, 
for some athletes, traditional paper and pencil neuropsychologi-
cal testing may be a component of concussion protocols. While 
neurocognitive evaluation is essential in assessing and managing 
concussion in a majority of cases, it is important to recognize that 
neurocognitive deficits are occasionally absent following concus-
sion. A recent meta-analysis of computerized neurocognitive 
tests (CNTs) suggests an overall low-to-moderate magnitude of 
effects size, attributing these findings to the heterogenic nature of 
concussion (38). There are other limitations in using neurocogni-
tive testing following concussion. Several extraneous factors may 
influence neurocognitive test performance, including motiva-
tion, effort, sleep, pain, and anxiety (39). Neurocognitive testing 
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can be challenging to interpret among subpopulations, such as 
individuals with learning disabilities or attention deficits in the 
absence of baseline testing (40).
postural stability/Vestibular
Assessing balance and postural stability may be useful in the acute 
stages of injury (25). The Balance Error Scoring System (BESS) is 
the most widely used balance assessment following concussion, 
due to its rapid ease of administration and low cost. However, the 
system’s sensitivity has been criticized because of the influence of 
other factors, such as fatigue, type of sport, and history of ankle 
injury or instability (41). The Sensory Organization Test (SOT) 
evaluates dynamics in postural stability using a force plate, and 
has superior reliability compared to the BESS (27). However, it is 
not feasible to use on the sideline due to the required equipment. 
Furthermore, similar to neurocognitive testing, deficits in postural 
stability are not always present after concussion or may resolve 
rapidly. Another tool developed for concussion assessment is the 
vestibular/ocular motor screening (VOMS) (28), which uses sev-
eral tests for screening central vestibular functioning, including 
the vestibular–ocular reflex and visual-motion sensitivity.
oculomotor assessment
Both subjective and objective measures of oculomotor function-
ing have utility in diagnosis and management of concussion. The 
VOMS measures near point of convergence and provocation of 
symptoms on saccades, both sensitive to concussion (28), and 
correlates with neurocognitive impairment (42). The King–
Devick (K–D) is a 1-min test in which the athlete is asked to read, 
quickly and accurately, several pages of single-digit numbers that 
are arrayed left to right in columns that do not vertically align 
(43). Preliminary evidence suggests K–D is easily administered, 
can differentiate concussed from non-concussed athletes, and has 
high test–retest reliability (r = 0.90) (44). However, there is con-
cern regarding practice effects (45). The objective eye-tracking 
technology concussion test, used in both sports and combat 
settings, records the subject visually tracking a target as it moves 
through a circular trajectory (46). Gaze error variability has 
been found to correlate significantly with attention and working 
memory measures on neurocognitive testing (29).
neUroiMaGinG
Concussion is generally regarded as a functional, rather than a 
structural, brain injury, with conventional neuroimaging findings 
considered normal and adding little value to clinical management 
of this injury beyond ruling out more severe pathology, such as a 
skull fracture or intracranial hemorrhage (47).
However, advanced magnetic resonance imaging (MRI) 
methods have demonstrated the ability to detect and local-
ize pathophysiologic consequences of concussion or mTBI 
(48). Functional MRI (fMRI) data have shown a strong link 
between brain region functioning vs. concussion severity and 
time to recovery; however, this procedure is used primarily in 
the research setting (49). Diffusion tensor imaging (DTI)/DTI-
based tractography is used to evaluate axonal tearing after the 
impact. Quantitative high-resolution imaging techniques, such as 
susceptibility-weighted imaging (SWI) or angiography (SWAN), 
depict iron deposits in brain microvessels, while cerebrovascular 
dysfunction in areas of hyper- or hypoperfusion can be detected 
by high-resolution diffusion-weighted imaging (DWI).
Recent studies that used SWI or perfusion-weighted imaging 
(PWI) with DTI and magnetic resonance (MR) spectroscopy 
found abnormalities in 80% of patients with mTBI when these 
three imaging modalities were collated (50, 51).
diffusor tensor imaging
Diffusion tensor imaging (3T DTI)-based tractography evaluates 
diffuse axonal injury (DAI). Additionally, 3T fluid-attenuated 
inversion recovery (FLAIR) imaging allows detection of non-
hemorrhagic DAI (47) and could potentially assist in assessment 
of structural abnormalities in concussions. Due to success in 
assessing a population with moderate-to-severe TBI, DTI has 
gained popularity for use in mTBI because of its enhanced 
technical resolution. DTI can reveal white matter alterations 
affecting the corticospinal tract (CST); the internal capsule; 
the corpus callosum (52); the inferior/superior, longitudinal, 
and fronto–occipital fasciculi; and the posterior thalamic and 
acoustic radiations in athletes following sports concussions (53). 
While increased fractional anisotropy (FA) numbers indicate 
reversible changes in white matter, reduced FA values reflect 
a loss of white matter integrity in a region of interest (54–56). 
Overall, data from DTI studies of mTBI have been contradictory, 
however, showing both increased FA values in acute and chronic 
studies (57, 58) as well as decreased FA levels (59). Recently, 
Davenport et al. (60) demonstrated that a single football season 
can produce alterations in DTI parameters in the absence of 
clinical concussion.
diffusion-Weighted imaging
Microvessel dysfunction can be detected by high-resolution 
DWI. DWI allows for differentiation between cytotoxic edema 
(restricted diffusion) and vasogenic edema (increased diffusion), 
and has been shown to identify shearing injuries not evident on 
T2/FLAIR or gradient echo sequences (61). Significant involve-
ment of the neurovascular unit has also been shown in pediatric 
patients with sports-related concussions who experienced persis-
tent symptoms (50). Recent MRI-based studies assessing cerebral 
flow alterations due to concussions and mTBI are indicating the 
emerging concept of concussion as a form of cerebrovascular 
disease (62).
susceptibility Weighted imaging
Small hemorrhages in white matter have been detected by 
high-resolution SWI in retrospective studies of retired NFL 
players (63), youths with sports-related concussion (64), and, in 
amateur boxers, more severe cases of mTBI (65). Significant SWI 
hypointensity alterations in brains of adult male hockey players 
within a single season have been observed in the subacute stage 
of injury compared to baseline images (66). However, SWI does 
not provide quantitative measures of magnetic susceptibility (67).
taBLe 3 | Candidate biomarkers for identification of concussions severity.
Biomarker performance characteristics strengths (intended use) Limitations (biomarker studies) reference
Cut off  
ng/ml
sensitivity  
%
specificity 
%
AMPAR peptide 0.4 89–91 91-92 Associated with diffuse axonal injury 
(DAI)
Need data assessed within 24 h after 
concussion
(77)
NMDAR peptide 1.0 83 91 A biomarker of microvessel damage 
and correlates with development of 
cortical vasogenic edema
Need to be assessed within 24 h after 
concussion
(5)
Calpain-derived αII-
spectrin N-terminal 
fragment (SNTF)
Not 
established
100 75 Associated with DAI and shows white 
matter abnormalities
Low levels in biological liquids for mTBI. 
There are no concussion studies
(78)
Breakdown products 
of glial fibrillary acidic 
protein (GFAP-BDP)
0.03 60–93 75–97 Detects hemorrhage/hematoma and 
might be used to reduce unnecessary 
CT/MRI
GFAP-BDP also releases during intracerebral 
and subarachnoid hemorrhagic strokes. 
There are no concussion studies
(79)
GFAB autoantibody 2.9–3.0 – – Shows dynamic interactions between 
post-injury and specific autoimmune 
response
Small sample size of the study (80)
Kainate receptor 
peptide
0.5 83–90 83–92 Might be associated with brainstem 
injury and regulates venous circulation 
(development of cytotoxic edema)
Need to be assessed within 24 h after 
concussion
(81)
S-100B 0.06 94 50 A marker of compromised blood–brain 
barrier
Lack of specificity (82)
0.12 29 96
Total Tau protein – Area under curve: 0.91 
(95% CI, 0.81-1.00)
Correlates to severity of concussions 
and predicts longevity of recovery
Small sample size of the study (83)
UCHL1 – Area under curve: 0.62 
(95% CI, 0.57–0.71)
A potential diagnostic assessment of 
acute TBI
UCHL1 found in more severe TBI. Limited 
concussion studies
(84, 85)
0.72 Associated with outcome
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susceptibility-Weighted angiography
As with SWI, SWAN focuses on intracerebral small vessels 
for identifying cerebral hemorrhage and calcifications (68) 
by visualizing measurable changes in cerebral veins due to 
hypoxia (69). It is particularly useful in visualizating micro-
hemorrhages and lesions near the skull base (70), and has con-
tributed to a proposed MRI grading scale (71, 72). Application 
of susceptibility-weighted imaging mapping (SWIM) for 
quantitative assessment (67) of venous blood oxygenation 
in the acute stage of mTBI has shown an excess of oxygen in 
impacted areas that may reflect a neuroprotective response 
following the injury (73).
In summary, several MRI sequences (DTI, DWI, FLAIR, 
SWI, SWAN) may be valuable in determining the location 
and level of microstructural abnormalities (micro-lesions) and 
edema following concussion. However, to date, MRI studies 
for mTBI are limited by study design, including consensus in 
methodology; e.g., 1.5 or 3T, sequence, slice thickness, and 
spatial resolution (74). Furthermore, there is often variability in 
timing after injury, age of subjects, severity of injury, and brain 
region analyzed. Additionally, use of advanced imaging-derived 
techniques, such as DTI, with multi-shell diffusion and high-
definition  tractography modeling might be useful in identifying 
subtle structural changes due to mild concussion (52). The 
development of universal and more inclusive protocol(s) for 
mTBI studies might help overcome current limitations in pursuit 
of comparable, reproducible data.
GLUtaMater reCeptor BioMarKers
Biomarkers for concussion can be categorized as diagnostic 
or prognostic/monitoring (75, 76). Prospective, diagnostic 
biomarkers provide information about a disease or condition 
and may assess the severity of concussion. Prognostic biomark-
ers (risk assessment) are defined as indicators that may provide 
the anticipated natural history of a disorder in the absence of 
a therapeutic intervention. Monitoring biomarkers (recovery) 
are used to follow a previously diagnosed or established disease 
or condition; for example, in making a decision whether a 
person should be returned to play in sports or to work or active 
military duty.
diagnostic potential
Ideal biomarker(s) for the diagnosis of concussion should 
(i) reflect the origin of transient subtle brain injury resulting from 
the impact and show a specific location of subtle brain injury, 
(ii) include detectable biological markers at an early stage of 
brain damage (within minutes to hours after event), (iii) correlate 
with performance on clinical measures, and (iv) demonstrate 
functional deficits or metabolic disturbances concurrent with 
advanced neuroimaging (fMRI, DTI, and SWI modalities). 
Several candidate brain biomarkers are associated with concus-
sion severity (Table 3).
Neurotoxicity biomarkers include the ionotropic GluRs. 
The AMPA receptors (AMPAR; GluR1 subtype) are located 
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exclusively in synaptic terminals (77) and could indicate diffuse 
dendritic–axonal injury (86). AMPAR is primarily distributed in 
the forebrain and subcortical pathways, including the hippocam-
pus, amygdala, thalamus, hypothalamus, and brain stem (87, 88). 
These regions of the brain are predictable sources of biomarkers 
given the functional spatial-temporal coherence, developmental 
pathways, and cerebral plasticity affected by mild brain injury 
(89). The NMDA receptors (NMDAR: NR2 subtypes) are 
localized on the epithelial surface of microvessels that form the 
BBB and regulate cerebral arterial microvascular function (90). 
The biomechanical forces that lead to concussion may cause 
mechanical damage and energy failure in parenchymal cells and 
endothelia that comprise the BBB. Furthermore, concussion 
drives neurotoxicity biomarker peptides to be released continu-
ously into the bloodstream through the compromised BBB within 
hours to days after impact. During the acute phase of concussion, 
a massive release of glutamate upregulates excitotoxic AMPAR 
(55, 91). The GluR1-subunit of N-terminal AMPAR fragments 
are rapidly cleaved by extracellular proteases and released into 
the bloodstream, where this degradation product, identified as 
a biomarker of neurotoxicity, can be directly detected (peptide 
fragment of 5–7 kD).
A feasibility study examining the diagnostic potential of 
the AMPAR peptide assay was conducted by administering 
neuropsychological testing (ImPACT) and neuroimaging to 
concussed athletes (20.8 ±  1.8  years old, 56M/28F, 1–2  weeks 
post-concussion, GCS  =  14–15) and age-, gender-matched 
healthy controls (21M/19F) in conjunction with measurements 
of the biomarker (86). The sensitivity (91%) and specificity (92%) 
of AMPAR peptide to assess acute and semi-acute concussions 
(preliminary cut off of 0.4 ng/mL) in college athletes was estab-
lished. Additionally, in athletes with multiple concussions, worse 
ImPACT scores on processing speed, reaction time, and cognitive 
efficiency correlated with abnormal levels of AMPAR peptide 
(2.0–12.0 ng/mL) and DAI changes apparent on MRI (2).
Kainate receptors (KAR, GluR5/6), which are located mostly 
in the hippocampus, subcortical areas, spinal cord tract, and 
brainstem (92), might potentially affect cerebral venous circu-
lation. Glutamate serves as a neuromediator for the medulla 
involved in regulation of involuntary life sustaining functions, 
such as breathing, swallowing, heart rate, and consciousness 
(92), primarily through KAR (2). In patients with mTBI, the 
decrease of venous function due to a rise in venous oxygenation 
in the affected thalamostriate and right basal areas (93) might 
involve KAR. As a component of post-military deployment 
mTBI screening, KAR peptide detection in active duty military 
personnel (37M/16F, 23.0 ± 1.2 years old, 1 week after blast injury, 
GCS = 13–15) with impaired venous circulation in cervical areas 
defined by dopplerography yielded an optimal cut-off value of 
1.0 ng/mL (90% sensitivity, 83% specificity), at which a positive 
predictive value of 93% was achieved. A clinical study conducted 
with civilians who sustained mTBI (25M/20F, 30.1 ± 3.0 years 
old, GCS =  13–15) and admitted to ED within 24  h after the 
impact due to violence-related events, motor vehicle crashes, 
and incidental falls showed KAR peptide sensitivity of 83% 
and specificity of 92% (cut-off of 0.5 ng/mL), with a significant 
positive likelihood ratio of 10.5 to assess severe concussions 
(unpublished data). Notably, AMPAR and NR2 peptides were 
also abnormal in these cohorts.
prognostic/Monitoring approaches
Biomarkers intended to measure recovery following concus-
sion should potentially (i) reflect neurological symptoms, (ii) 
identify the immune system response to inflammation, (iii) 
further predict outcomes, and (iv) assist with treatment/therapy 
recommendations.
Disruption of the BBB due to biomechanical force is believed 
to cause instantaneous increase in brain vasculature permeabil-
ity, with both immediate and delayed pathogenic consequences 
(7, 94). The effects of a compromised BBB are exacerbated when 
accompanied by an immunological response initiated by entry 
of peripheral anti-CNS autoantibodies (95–97), which may be 
prognostic biomarkers of brain injury (98). Due to the nature 
of the normal immune response, antibodies to brain antigens 
detected in serum are typically associated with advanced or 
chronic conditions of brain damage (99, 100), whereas neuronal 
antigens measured in plasma are more likely to reflect acute 
injuries (101).
Early experimental and clinical research of antibodies to 
GluR1 subtype of AMPA receptors as an immunoexcitotoxicity 
biomarker has demonstrated their diagnostic value in detect-
ing pathological brain-spiking activity and epileptic seizures 
(102, 103) as a consequence of traumatic brain injury, thereby 
representing a prognostic risk factor. Above threshold increases 
of AMPAR antibodies measured in serum of children (n = 60, 
7–16  years old) with chronic posttraumatic headache within 
6–12 months after sustained single or multiple concussions were 
correlated with abnormal brain-spiking activity on EEG (104). 
Clinical studies of GluR1 antibodies in adult patients with dif-
ferent chronic neurological pathology (n  =  1866) performed 
in Russia, Europe, and the USA have demonstrated diagnostic 
potential (sensitivity of 86–88%, specificity of 83–97%) in assess-
ment of seizures (epilepsy) as consequence of sustained single or 
multiple concussions (105, 106).
One potential prognostic biomarker is a marked increase in 
the level of NR2 antibodies. These increased levels are evidence 
of persistent brain changes related to delayed cerebral ischemia 
(107), which can follow concussion. In three subjects with prior 
concussion, NR2 antibody levels remained elevated beyond the 
cut-off (2.0 ng/mL) throughout the 1.5-year study duration (2). 
Interestingly, visual memory composite scores on ImPACT were 
impaired in two of the three athletes. Furthermore, reduction 
in NR2 peptide and antibodies threshold levels corresponded 
with improvement on ImPACT scores and reduction of post-
concussive symptoms.
An AMPAR peptide assay has been evaluated as a tool for 
management and decision making for return to play, work, and 
active military duty following concussion. In a longitudinal study, 
initial assessment of AMPAR peptide in athletes showed that of 
84 subjects (20.8 ± 1.8 years old, 56M/28F, 1–2 weeks post-con-
cussion, GCS = 14–15), 18 (21%) had increased biomarker levels 
after concussion (108). In the subsequent 15  months, AMPAR 
peptide values decreased in 11 of the 18 subjects (61%), with 
levels close to normal (0.07–0.9 ng/mL). These athletes also had 
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normal ImPACT scores, and were allowed to return to play. After 
an additional 3 months, the seven remaining athletes remained 
symptomatic and had higher AMPAR peptide values compared 
to controls. Consequently, they were advised to postpone their 
return to playing sports and directed to neuroimaging (2).
A recent prospective off-season study assessed AMPAR 
peptide levels in a professional American football team. Among 
players (43M, 27.8  ±  3.1) who had no concussions reported 
in the prior season, AMPAR peptide levels in plasma (within 
0.1–1.0 ng/mL) cleared 40 players (93%) to play. The remaining 
three players (7%) were advised to postpone return to play due 
to higher AMPAR peptide levels (1.2–2.3 ng/mL). Interestingly, 
two out of the three players with elevated AMPAR peptide levels 
reported concussion a week before blood draw, suggesting a 
cumulative effect. Preliminary assessment of assay performance 
characteristics in semi-acute (within 2  weeks after the concus-
sion) assessment yielded an 89% sensitivity and 91% specificity 
(unpublished data).
impaired neuroplasticity Biomarkers  
for Concussion (acute and Chronic 
Conditions)
Due to breakdown of the BBB, most proteins responsible for 
impaired neuroplasticity enter the bloodstream, fluids, and tis-
sues relatively late (109). Among these are the calpain-derived 
αII-spectrin N-terminal fragment (SNTF) (78, 110), αII-spectrin 
breakdown products (SBDPs) for axonal injury (111), S100 asso-
ciated with compromised BBB (112), astrocyte-specific protein 
glial fibrillary acidic protein (GFAP), a biomarker of hematoma/
hemorrhage (113) and GFAP autoantibody as a post-injury 
autoimmune response (80), tau protein, a microtubule-associated 
structural protein located within axons, and ubiquitin carboxy-
terminal hydrolase L1 (UCHL1), a cysteine protease expressed in 
neurons as well as neuroendocrine cells (114) (Table 3).
Following TBI, SNTF accumulates in axons and blood. In a 
study of patients with mTBI admitted to an emergency room, 
blood SNTF levels correlated with white matter abnormalities on 
DTI, as well as cognitive dysfunction and persisted for at least 
3 months (110). Among professional ice hockey players, serum 
SNTF increased at 1  h after concussion and remained signifi-
cantly elevated from 12 h to 6 days, before declining to preseason 
baseline. By contrast, serum SNTF levels were unchanged after 
training in healthy controls (78). Serum SNTF exhibited sufficient 
diagnostic accuracy for delayed return to play in this study (area 
under the curve = 0.87).
S100 proteins are small acidic proteins with diverse functions 
that range from cell cycle progression, transcription protection 
from oxidative cell damage, and apoptosis (115, 116). A study of 
collegiate and semi-professional athletes who completed S100B 
testing at baseline and following concussion demonstrated that 
relative and absolute increase in serum S100B could accurately 
distinguish concussion from sport-related exertion (82). A cor-
relation between S100B levels and number of sub-concussive 
head hits has also been reported (117). Other studies have 
suggested that low levels of S100B were able to rule out mTBI 
(118, 119). Recent studies have demonstrated that measurement 
of S100B would assist in indicating if a CT scan would be needed 
in the acute setting (120–122). The transient disruption of the 
BBB from multiple sub-concussive and/or concussive events 
may allow accumulation of S100B autoantibodies that could be 
associated with predisposition to neurological disease, including 
chronic traumatic encephalopathy (CTE). Despite prolonged 
rest, repetitive head impacts sustained in contact sports have 
been shown to cause persistent white matter alterations (123). 
Thus, S100B autoantibodies may be useful biomarker after acute 
concussion and in evaluating more chronic consequences of 
head trauma.
Two studies have shown that serum GFAP and its breakdown 
products (GFAP-BDP), markers of hemorrhage, were increased 
in patients with an abnormal CT compared to those with a 
normal CT after mTBI (124, 125). GFAP remained elevated in 
axonal injury on MRI in a subset of mTBI patients at 3 months’ 
post-injury (124). Similarly, serum GFAP-BDP was significantly 
higher in patients with intracranial lesions on CT, compared with 
those without lesions, and was able to predict which patients 
required neurosurgical intervention (113). A recent study of 
396 patients with mild-to-moderate TBI established that GFAP 
out-performed S100B in detecting intracranial CT lesions, par-
ticularly in the setting of extracranial fractures (126). GFAP-BDP 
demonstrated very good predictive ability (AUC = 0.87) as well as 
significant discrimination of injury severity (125). Recent study 
detecting GFAP autoantibodies found three to five times higher 
biomarker values in chronic and acute cases accompanies with 
prior TBI (80). However, it is unclear if serum GFAP would be 
useful in detecting a more mild form of TBI, such as a sports-
related concussion.
Ubiquitin carboxy-terminal hydrolase L1 levels in CSF and 
serum demonstrated predictive value for severe TBI in adult and 
children (127, 128) and were also increased after seizures (129). 
It was suggested that UCHL1 is potentially reporting the BBB 
integrity (94). Assessments of UCH-L1 after sport-related sub-
concussive head hits displayed lack of clinical significance (117).
Tau protein is a microtubule-associated structural protein 
located within axons. The deposition of hyperphosphorylated tau 
(p-tau) protein in clusters around small blood vessels of the cortex 
is indicative of tauopathy and is related to CTE (130). Although 
the factors that contribute to CTE are poorly understood, both 
professional athletes (131) and military veterans (132) have been 
diagnosed with this disease. To date, CTE is primarily diagnosed 
postmortem (133); however, the first attempt to detect total tau 
protein in plasma using digital array technology (Table  3) has 
recently been reported (83).
disCUssion
Clinical assessment tools for concussion all represent functional 
biomarkers. These include symptom report, neurocognitive 
testing, and postural stability/vestibular and oculomotor assess-
ments. While widely used to guide clinical care, concern regard-
ing the sensitivity of these functional biomarkers as well as their 
feasibility for use in the sports arena exists. For example, sideline 
testing is brief and, therefore, may not be sensitive enough to 
identify mild concussion. Comprehensive neurocognitive 
taBLe 4 | proposed functional, metabolic, and structural biomarkers to assess severity of acute concussions and mtBi.
neuroanatomical area of injury Clinical and neuropsychological 
scores
neurotoxicity  
markersc
proposed scores 
GCs impaCta sCat3b 3t (or higher) Mrid GCs/Mri/biomarkers
preferable modality scores
Subcortical dendritic-axonal injury (DAI) 15 0.3–0.4 19.3 AMPAR (A) DTI 1 15A1
Cortical–subcortical, subcortical–cervical 
area, or cortical–cervical area, transient 
events (vasogenic edema)
14 0.2–0.3 40.7 AMPAR (A) NR2(N)  
KAR(K)
DWI, DTI 2 14 AN2 –cortical 
– subcortical
14AK2 – subcortical 
–cervical 
14NK2- cortical–cervical
Cortical-subcortical and cervical area 
(cytotoxic edema)
12–13 0.1–0.2 46.2 Overall involvement of 
ionotropic GluRs ANK
FLAIR, SWI/SWAN, 
DTI
3 12ANK3
13ANK3
aConsidered only cognitive efficacy score.
bSCAT3 data were considered from (21).
cConsidered only abnormal values of AMPAR, AMPA receptor peptide fragment (candidate biomarker of DAI); NR2, peptide fragment of NMDA receptor subtype (arterial 
microvascular marker candidate); KAR, kainite receptor peptide fragment (venous circulation biomarker candidate).
dMRI scores are suggested analog to that proposed by Potapov et al. (71) based on location/level of brain lesions for TBI.
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testing may appear normal, leading to premature return to 
play. More objective means of assessment, including advanced 
neuroimaging techniques and neurotoxicity biomarkers, have 
gained research attention. These measures may facilitate diag-
nosis and potentially assist with monitoring a subject’s recovery. 
Preliminary studies suggest neurotoxicity biomarkers, in con-
junction with neurocognitive testing, may improve diagnostic 
certainty of suspected concussions as well as provide valuable 
information on prognosis, allowing a clinician to modify treat-
ment recommendations.
This review highlights potential structural and neurotoxicity 
biomarkers that could be integrated into the current clinical 
concussion evaluation that, at present, relies primarily on func-
tional biomarkers. Research to date supports a move toward 
administering a more comprehensive panel of biomarkers; 
namely, neurotoxicity markers. These biomarkers represent a 
second generation of brain “tracers” that could be used to deci-
pher the microstructural abnormalities observed on advanced 
neuroimaging. For example, abnormal values of one (15A1), two 
(14AN2, 14NK2, 14 AK2), or three GluRs (12-13ANK3) may 
assist in making a decision to return a subject to play, extended 
rest, or further medical assistance (Table  4). Those athletes or 
patients with abnormal scores using these biomarkers should be 
directed to neuroimaging assessment (DTI, DWI, SWI, FLAIR), 
and may benefit from an individualized treatment plan. In the 
future, it may be possible to classify concussion severity with 
neuroimaging, similar to proposed MRI classification for TBI 
(71). Furthermore, the use of neurotoxicity biomarkers may assist 
radiologists with additional information concerning the area of 
interest, where microstructural changes might be located (corti-
cal, subcortical, or brainstem injuries).
Accurate diagnosis of concussion and appropriate manage-
ment of the injury to prevent premature return to play is vital to 
protecting the long-term brain health of athletes and others at risk 
of re-injury. Structural and neurotoxicity biomarkers can be used 
to complement the functional biomarkers currently used to assess 
concussion to facilitate diagnosis and treatment.
HUMan sUBJeCts
This review presents retrospective analyses of neurotoxicity 
biomarkers measured in subjects with concussions and mild TBI 
previously disclosed in peer-reviewed scientific publications.
All retrospective analyses of human data concerning GluR 
biomarker studies conducted by the authors were performed in 
accordance with institutional and national guidelines and regula-
tions. The institutional review protocol governing the college and 
professional athletes’ enrollment was approved by the respective 
Institutional Review Boards at Kennesaw State University, the 
University of Pittsburgh, and by the USAMRMC ORP HRPO 
under proposal DM090557 (award W81XWH-11-2-0081). The 
research protocol for using samples collected from active duty 
personnel and civilians who suffered mild TBI in the studies 
described herein were approved by the Ethics Committee at 
Burdenko Institute of Neurosurgery (Moscow, Russia). Written 
informed consent was provided by all research subjects. The pri-
vacy of participants was protected using global unique identifiers.
aUtHor ContriBUtions
SD and JDM are joint senior authors. AMS, JDM, EVA, and AAP 
are contributed equally to this work.
FUndinG
In parts supported by grant from US Army Medical Research 
and Materiel Command, 2011–2013 and grant from Skolkovo 
BioMed, Moscow, Russia, 2016–2017.
9Dambinova et al. Integrative Assessment of Concussions
Frontiers in Neurology | www.frontiersin.org October 2016 | Volume 7 | Article 172
reFerenCes
1. Collins MW, Kontos AP, Reynolds E, Murawski CD, Fu FH. A comprehensive, 
targeted approach to the clinical care of athletes following sport-related con-
cussion. Knee Surg Sports Traumatol Arthrosc (2014) 22:235–46. doi:10.1007/
s00167-013-2791-6 
2. Dambinova SA, Sowell RL, Maroon J. Gradual return to play: potential role 
of neurotoxicity biomarkers in assessment of concussions severity. J Mol 
Biomark Diagn (2013) 3(Suppl1):S003. doi:10.4172/2155-9929.S3-003 
3. Lebrun CM, Mrazik M, Prasad AS, Tjarks BJ, Dorman JC, Bergeron MF, et al. 
Sport concussion knowledge base, clinical practises and needs for continuing 
medical education: a survey of family physicians and cross-border compari-
son. Br J Sports Med (2012) 47:54–9. doi:10.1136/bjsports-2012-091480 
4. Zehtabchi S, Sinert R, Soghoian S, Liu Y, Carmody K, Shah L, et al. Identifying 
traumatic brain injury in patients with isolated head trauma: are arterial 
lactate and base deficit as helpful as in polytrauma? Emerg Med J (2007) 
24:333–5. doi:10.1136/emj.2006.044578 
5. Dambinova SA, Bettermann K, Glynn T, Tews M, Olson D, Weissman JD, 
et al. Diagnostic potential of the NMDA receptor peptide assay for acute isch-
emic stroke. PLoS One (2012) 7:e42362. doi:10.1371/journal.pone.0042362 
6. McCrory P, Meeuwisse WH, Aubry M, Cantu B, Dvorák J, Echemendia RJ, 
et  al. Consensus statement on concussion in sport: the 4th International 
Conference on Concussion in Sport held in Zurich. Br J Sports Med (2013) 
47:250–8. doi:10.1136/bjsports-2013-092313 
7. Blennow K, Hardy J, Zetterberg H. The neuropathology and neurobi-
ology of traumatic brain injury. Neuron (2012) 76:886–99. doi:10.1016/ 
j.neuron.2012.11.021 
8. Choe MC, Babikian T, DiFiori J, Hovda DA, Giza CC. A pediatric perspec-
tive on concussion pathophysiology. Curr Opin Pediatr (2012) 24:689–95. 
doi:10.1097/MOP 
9. Khurana VG, Kaye AH. An overview of concussion in sport. J Clin Neurosci 
(2012) 19:1–11. doi:10.1016/j.jocn.2011.08.002 
10. Guskiewicz KM, Mihalik JP. Biomechanics of sport concussion: quest for the 
elusive injury threshold. Exerc Sport Sci Rev (2011) 39:4–11. doi:10.1097/
JES.0b013e318201f53e 
11. Johnston SC, Albers GW, Gorelick PB, Cumbler E, Klingman J, Ross MA, 
et  al. National Stroke Association recommendations for systems of care 
for transient ischemic attack. Ann Neurol (2011) 69:872–7. doi:10.1002/
ana.22332 
12. King D, Hume P, Gissane C, Brughelli M, Clark T. The influence of head 
impact threshold for reporting data in contact and collision sports: systematic 
review and original data analysis. Sports Med (2016) 46:151–69. doi:10.1007/
s40279-015-0423-7 
13. Bailes JE, Petralia AL, Omalu BI, Nauman E, Talavage T. Role of subconcussion 
in repetitive mild traumatic brain injury. J Neurosurg (2013) 119:1235–45. 
doi:10.3171/2013.7.JNS121822 
14. Rezaei A, Karami G, Ziejewski M. Examination of brain Injury thresholds 
in terms of the severity of head motion and the brain stresses. Intern 
Neurotrauma Lett (2014) 35. Available from: http://www.internationalbrain.
org/examination-of-bi-thresholds-in-terms-of-the-severity-of-head- 
motion-and-the-brain-stresses/
15. Okonkwo DO, Tempel ZJ, Maroon J. Sideline assessment tools for the evalua-
tion of concussion in athletes: a review. Neurosurg (2014) 75(Suppl 4):S82–95. 
doi:10.1227/NEU.0000000000000493 
16. Kutcher JS, McCrory P, Davis G, Ptito A, Meeuwisse WH, Broglio SP. What 
evidence exists for new strategies or technologies in the diagnosis of sports 
concussion and assessment of recovery? Br J Sports Med (2013) 47:299–303. 
doi:10.1136/bjsports-2013-092257 
17. Breedlove EL, Robinson M, Talavage TM, Morigaki KE, Yoruk U, O’Keefe K, 
et al. Biomechanical correlates of symptomatic and asymptomatic neurophys-
iological impairment in high school football. J Biomech (2012) 45:1265–72. 
doi:10.1016/j.jbiomech.2012.01.034 
18. Chen Y, Peng Y, Li F, Yang JK, Otte D. Brain injury for vulnerable road users in 
vehicle accidents using mathematical models. In: Lim CT, Goh JCH, editors. 
IFMBE Proceedings WCB 2010, 6th World Congress of Biomechanics (WCB 
2010) (Vol. 31), Singapore, Malaysia: Springer (2010). p. 497–500.
19. Guskiewicz KM, Mihalik JP, Shankar V, Marshall SW, Crowell DH, 
Oliaro  SM, et  al. Measurement of head impacts in collegiate football 
players: relationship between head impact biomechanics and acute clin-
ical outcome after concussion. Neurosurg (2007) 61:1244–52. doi:10.1227/ 
01.neu.0000306103.68635.1a 
20. Zhang L, Yang KY, King AI. A proposed injury threshold for mild traumatic 
brain injury. J Biomech Eng (2004) 126:226–36. doi:10.1115/1.1691446 
21. Guskiewicz KM, Register-Mihalik J, McCrory P, McCrea M, Johnston  K, 
Makdissi M, et  al. Evidence-based approach to revising the SCAT2: 
introducing the SCAT3. Br J Sports Med (2013) 47:289–93. doi:10.1136/
bjsports-2013-092225 
22. Kontos AP, Sufrinko A, Womble M, Kegel N. Neuropsychological assessment 
following concussion: an evidence-based review of the role of neuropsycho-
logical assessment pre-and post-concussion. Curr Pain Headache Rep (2016) 
20:38. doi:10.1007/s11916-016-0571-y 
23. Resch J, McCrea M, Cullum CM. Computerized neurocognitive testing in 
the management of sport-related concussion: an update. Neuropsychol Rev 
(2013) 23:335–49. doi:10.1007/s11065-013-9242-5 
24. Coldren RL, Russell ML, Parish RV, Dretsch M, Kelly MP. The ANAM 
lacks utility as a diagnostic or screening tool for concussion more than 
10 days following injury. Mil Med (2012) 177:179–83. doi:10.7205/
MILMED-D-11-00278 
25. Guskiewicz KM. Assessment of postural stability following 
sport-related concussion. Curr Sports Med Rep (2003) 2:24–30. 
doi:10.1249/00149619-200302000-00006 
26. Valovich TC, Perrin DH, Gansneder BM. Repeat administration elicits 
a practice effect with the balance error scoring system but not with the 
Standardized Assessment of Concussion in high school athletes. J Athl Train 
(2003) 38:51–6. 
27. Broglio SP, Ferrara MS, Sopiarz K, Kelly MS. Reliable change of the 
sensory organization test. Clin J Sport Med (2008) 18:148–54. doi:10.1097/
JSM.0b013e318164f42a 
28. Mucha A, Collins MW, Elbin RJ, Furman JM, Troutman-Enseki C, 
DeWolf RM, et al. A brief vestibular/ocular motor screening (VOMS) assess-
ment to evaluate concussions: preliminary findings. Am J Sports Med (2014) 
42:2479–86. doi:10.1177/0363546514543775 
29. Samadani U, Ritlop R, Reyes M, Nehrbass E, Li M, Lamm E, et al. Eye tracking 
detects disconjugate eye movements associated with structural traumatic 
brain injury and concussion. J Neurotrauma (2015) 32:548–56. doi:10.1089/
neu.2014.3687 
30. King D, Brughelli M, Hume P, Gissane C. Concussions in amateur rugby 
union identified with the use of a rapid visual screening tool. J Neurol Sci 
(2013) 326:59–63. doi:10.1016/j.jns.2013.01.012 
31. Echemendia RJ, Iverson GL, McCrea M, Macciocchi SN, Gioia GA, 
Putukian  M, et  al. Advances in neuropsychological assessment of 
sport-related concussion. Br J Sports Med (2013) 47:294–8. doi:10.1136/
bjsports-2013-092186 
32. Giza CC, Kutcher JS, Ashwal S, Barth J, Getchius TS, Gioia GA, et  al. 
Summary of evidence-based guideline update: evaluation and management 
of concussion in sports: report of the Guideline Development Subcommittee 
of the American Academy of Neurology. Neurology (2013) 80:2250–7. 
doi:10.1212/WNL.0b013e31828d57dd 
33. McLeod TC, Leach C. Psychometric properties of self-report concussion 
scales and checklists. J Athl Train (2012) 47:221–3. 
34. McCrea M, Kelly JP, Randolph C, Kluge J, Bartolic E, Finn G, et  al. 
Standardized assessment of concussion (SAC): on-site mental status 
evaluation of the athlete. J Head Trauma Rehabil (1998) 13:27–35. 
doi:10.1097/00001199-199804000-00005 
35. Barker JM, Wright DW, Goldstein FC, Ockerman J, Ratcliff JJ, Laplaca MC. 
The DETECT System: portable, reduced-length neuropsychological testing 
for mild traumatic brain injury via a novel immersive environment. J Med 
Eng Technol (2007) 31:161–9. doi:10.1080/0309190050027281 
36. Iverson GL, Brooks BL, Collins MW, Lovell MR. Tracking neuropsycho-
logical recovery following concussion in sport. Brain Inj (2006) 20:245–52. 
doi:10.1080/02699050500487910 
37. McClincy MP, Lovell MR, Pardini J, Collins MW, Spore MK. Recovery from 
sports concussion in high school and collegiate athletes. Brain Inj (2006) 
20:33–9. doi:10.1080/02699050500309817 
38. Kontos AP, Braithwaite R, Dakan S, Elbin RJ. Computerized neurocognitive 
testing within 1 week of sport-related concussion: meta-analytic review and 
10
Dambinova et al. Integrative Assessment of Concussions
Frontiers in Neurology | www.frontiersin.org October 2016 | Volume 7 | Article 172
analysis of moderating factors. J Int Neuropsychol Soc (2014) 20:324–32. 
doi:10.1017/S1355617713001471 
39. De Marco AP, Broshek DK. Computerized cognitive testing in the manage-
ment of youth sports-related concussion. J Child Neurol (2016) 31:68–75. 
doi:10.1177/0883073814559645 
40. Elbin RJ, Kontos AP, Kegel N, Johnson E, Burkhart S, Schatz P. Individual and 
combined effects of LD and ADHD on computerized neurocognitive concus-
sion test performance: evidence for separate norms. Arch Clin Neuropsychol 
(2013) 28:476–84. doi:10.1093/arclin/act024 
41. Furman GR, Lin C-C, Bellanca JL, Marchetti GF, Collins MW, Whitney SL. 
Comparison of the balance accelerometer measure and balance error 
scoring system in adolescent concussions in sports. Am J Sports Med (2013) 
41:1404–10. doi:10.1177/0363546513484446 
42. Pearce KL, Sufrinko A, Lau BC, Henry L, Collins MW, Kontos AP. Near point 
of convergence after a sport-related concussion: measurement reliability and 
relationship to neurocognitive impairment and symptoms. Am J Sports Med 
(2015) 43:3055–61. doi:10.1177/0363546515606430 
43. Vartiainen MV, Holm A, Peltonen K, Luoto TM, Iverson G, Hokkanen L. 
King-Devick test normative reference values for professional male ice hockey 
players. Scand J Med Sci Sports (2015) 25:e327–30. doi:10.1111/sms.12307 
44. Leong DF, Balcer LJ, Galetta SL, Evans G, Gimre M, Watt D. The King–Devick 
test for sideline concussion screening in collegiate football. J Optom (2015) 
8:131–9. doi:10.1016/j.optom.2014 
45. Galetta KM, Brandes LE, Maki K, Dziemianowicz MS, Laudano E, Allen M, 
et al. The King–Devick test and sports-related concussion: study of a rapid 
visual screening tool in a collegiate cohort. J Neurol Sci (2011) 309:34–9. 
doi:10.1016/j.jns.2011.07.039 
46. Maruta J, Tong J, Lee SW, Iqbal Z, Schonberger A, Ghajar J. EYE-TRAC: 
monitoring attention and utility for mTBI. Proceedings SPIE 8371: Sensing 
Technologies for Global Health, Military Medicine, Disaster Response, 
and Environmental Monitoring II; and Biometric Technology for Human 
Identification IX, 83710L, Baltimore, Maryland (2012). doi:10.1117/12.927790
47. Mechtler LL, Dhsdtri KK, Crutchfield KE. Advanced neuroimaging of 
mild traumatic brain injury. Neurol Clin (2014) 32:31–58. doi:10.1016/ 
j.ncl.2013.08.002 
48. Bigler ED. Neuroimaging biomarkers in mild traumatic brain injury (mTBI). 
Neuropsychol Rev (2013) 23:169–209. doi:10.1007/s11065-013-9237-2 
49. Lovell MR, Pardini JE, Welling J, Collins MW, Bakal J, Lazar N, et  al. 
Functional brain abnormalities are related to clinical recovery and time 
to return-to-play in athletes. Neurosurgery (2007) 61:352–9. doi:10.1227/ 
01.NEU.0000279985.94168.7F 
50. Kou Z, Wu Z, Tong KA, Holshouser B, Benson RR, Hu J, et al. The role of 
advanced MR imaging findings as biomarkers of traumatic brain injury. J Head 
Trauma Rehabil (2010) 25:267–82. doi:10.1097/HTR.0b013e3181e54793 
51. Bartnik-Olson BL, Holshouser B, Wang H, Grube M, Tong K, Wong V, 
et al. Impaired neurovascular unit function contributes to persistent symp-
toms after concussion: a pilot study. J Neurotrauma (2014) 31:1497–506. 
doi:10.1089/neu.2013.3213 
52. Delouche A, Attyé A, Heck O, Grand S, Kastler A, Lamalle L, et  al. 
Diffusion MRI: pitfalls, literature review and future directions of research 
in mild traumatic brain injury. Eur J Radiol (2016) 85:25–30. doi:10.1016/ 
j.ejrad.2015.11.004 
53. Chong CD, Schwedt TJ. White matter damage and brain network alterations 
in concussed patients: a review of recent diffusion tensor imaging and 
resting-state functional connectivity data. Curr Pain Headache Rep (2015) 
19:485. doi:10.1007/s11916-015-0485-0 
54. Wintermark M, Sanelli PC, Anzai Y, Tsiouris AJ, Whitlow CT; ACR Head 
Injury Institute. Imaging evidence and recommendations for traumatic brain 
injury: conventional neuroimaging techniques. J Am Coll Radiol (2015) 
12:e1–14. doi:10.1016/j.jacr.2014.10.014 
55. Dimou S, Lagopoulos J. Toward objective markers of concussion in sport: 
a review of white matter and neurometabolic changes in the brain after 
sport-related concussion. J Neurotrauma (2014) 31:413–24. doi:10.1089/
neu.2013.3050 
56. Shenton ME, Hamoda HM, Schneiderman JS, Bouix S, Pasternak O, Rathi Y, 
et al. A review of magnetic resonance imaging and diffusion tensor imaging 
findings in mild traumatic brain injury. Brain Imaging Behav (2012) 6:137–92. 
doi:10.1007/s11682-012-9156-5 
57. McAllister TW, Ford JC, Ji S, Beckwith JG, Flashman LA, Paulsen K, et al. 
Maximum principal strain and strain rate associated with concussion diag-
nosis correlates with changes in corpus callosum white matter indices. Ann 
Biomed Eng (2012) 40:127–40. doi:10.1007/s10439-011-0402-6 
58. Henry LC, Tremblay J, Tremblay S, Lee A, Brun C, Lepore N, et al. Acute 
and chronic changes in diffusivity measures after sports concussion. 
J Neurotrauma (2011) 28:2049–59. doi:10.1089/neu.2011.1836 
59. Lipton ML, Kim N, Zimmerman ME, Kim M, Stewart WF, Branch CA, et al. 
Soccer heading is associated with white matter microstructural and cognitive 
abnormalities. Radiology (2013) 268:850–7. doi:10.1148/radiol.13130545 
60. Davenport EM, Apkarian K, Whitlow CT, Urban JE, Jensen JH, Szuch E, 
et  al. Abnormalities in diffusional kurtosis metrics related to head impact 
exposure in a season of high school varsity football. J Neurotrauma (2016). 
doi:10.1089/neu.2015.4267 
61. Huisman TA, Sorensen AG, Hergan K, Gonzalez RG, Schaefer PW. 
Diffusion-weighted imaging for the evaluation of diffuse axonal 
injury in closed head injury. J Comput Assist Tomogr (2003) 27:5–11. 
doi:10.1097/00004728-200301000-00002 
62. Ellis MJ, Ryner LN, Sobszyk O, Fierstra J, Mikulis DJ, Fisher JA, et  al. 
Neuroimaging assessment of cerebrovascular reactivity in concussion: cur-
rent concepts, methodological considerations, and review of the literature. 
Front Neurol (2016) 7:61. doi:10.3389/fneur.2016.00061 
63. Casson IR, Viano DC, Haacke EM, Kou Z, LeStrange DG. Is there chronic 
brain damage in retired NFL players? neuroradiology, neuropsychology, and 
neurology examinations of 45 retired players. Sports Health (2014) 6:384–95. 
doi:10.1177/1941738114540270 
64. Ellis MJ, Leiter J, Hall T, McDonald PJ, Sawyer S, Silver N, et al. Neuroimaging 
findings in pediatric sports-related concussion. J Neurosurg Pediatr (2015) 
16:241–7. doi:10.3171/2015.1.PEDS14510 
65. Hasiloglu ZI, Albayram S, Selcuk H, Ceyhan E, Delil S, Arkan B, et  al. 
Cerebral microhemorrhages detected by susceptibility-weighted imaging in 
amateur boxers. AJNR Am J Neuroradiol (2011) 32:99–102. doi:10.3174/ajnr. 
A2250 
66. Helmer KG, Pasternak O, Fredman E, Preciado RI, Koerte IK, Sasaki T, 
et al. Hockey concussion education project, part 1. Susceptibility-weighted 
imaging study in male and female ice hockey players over a single season. 
J Neurosurg (2014) 120:864–72. doi:10.3171/2013.12.JNS132093 
67. Liu C, Li W, Tong KA, Yeom KW, Kuzminski S. Susceptibility-weighted 
imaging and quantitative susceptibility mapping in the brain. J Magn Reson 
Imaging (2015) 42:23–41. doi:10.1002/jmri.24768 
68. Docampo J, Gonzalez N, Bravo F, Sarroca D, Morales C, Bruno C. 
Susceptibility-weighted angiography of intracranial blood products and 
calcifications compared to gradient echo sequence. Neuroradiol. J (2013) 
26:493–500. doi:10.1177/197140091302600501 
69. Patzig M, Feddersen B, Haegler K, Olzowy B, Mees K, Fischer R, et  al. 
Susceptibility-weighted angiography visualizes hypoxia in cerebral veins. 
Invest Radiol (2015) 50:397–400. doi:10.1097/RLI.0000000000000143 
70. Hayashida Y, Kakeda S, Hiai S, Ide S, Ogasawara A, Ooki H, et al. Diagnosis 
of intracranial hemorrhagic lesions: comparison between 3D-SWAN (3D 
T2*-weighted imaging with multi-echo acquisition) and 2D-T2*-weighted 
imaging. Acta Radiol (2014) 55:201–7. doi:10.1177/0284185113495836 
71. Potapov AA, Zarharova NE, Kornienko VN, Pronin IN, Alexandrova EV, 
Zaitsev OS, et al. Neuroanatomical foundations for traumatic coma: clinical 
and magnetic resonance correlates. Zh Vopr Neirokhir Im N N Burdenko 
(2014) 78:4–13. 
72. Zakharova N, Kornienko V, Potapov A, Pronin I. Neuroimaging of Traumatic 
Brain Injury. Heidelberg: Springer (2014). p. 35–68.
73. Doshi H, Wiseman N, Liu J, Wang W, Welch RD, O’Neil BJ, et al. Cerebral 
hemodynamic changes of mild traumatic brain injury at the acute stage. PLoS 
One (2015) 10:e0118061. doi:10.1371/journal.pone.0118061 
74. Gardner A, Iverson GL, Stanwell P. A systematic review of proton magnetic 
resonance spectroscopy findings in sport-related concussion. J Neurotrauma 
(2014) 31:1–18. doi:10.1089/neu.2013.3079 
75. Sahu P, Pinkalwar N, Dubey RD, Rapoha S, Chatterjee S, Chatterjee T. 
Biomarkers: an emerging tool for diagnosis of a disease and drug develop-
ment. Asian J Res Pharm Sci (2011) 1:9–16. 
76. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol (2012) 6:140–6. 
doi:10.1016/j.molonc.2012.01.010 
11
Dambinova et al. Integrative Assessment of Concussions
Frontiers in Neurology | www.frontiersin.org October 2016 | Volume 7 | Article 172
77. Ashby MC, Daw MI, Issac JTR. AMPA Receptors. In: Gereau RW IV, Swanson 
GT, editors. The Glutamate Receptors. Totowa: Humana Press (2008). p. 1–44.
78. Siman R, Shahim P, Tegner Y, Blennow K, Zetterberg H, Smith DH. Serum 
SNTF increases in concussed professional ice hockey players and relates to the 
severity of postconcussion symptoms. J Neurotrauma (2015) 32:1294–300. 
doi:10.1089/neu.2014.3698 
79. Papa L, Brophy GM, Welch RD, Lewis LM, Braga CF, Tan CN, et al. Time 
course and diagnostic accuracy of glial and neuronal blood biomarkers 
GFAP and UCH-L1 in a large cohort of trauma patients with and without 
mild traumatic brain injury. JAMA Neurol (2016) 73:551–60. doi:10.1001/
jamaneurol.2016.0039 
80. Wang KK, Yang Z, Yue JK, Zhang Z, Winkler EA, Puccio AM, et al. Plasma 
anti-glial fibrillary acidic protein autoantibody levels during the acute and 
chronic phases of traumatic brain injury: a transforming research and clin-
ical knowledge in traumatic brain injury pilot study. J Neurotrauma (2016) 
33:1270–7. doi:10.1089/neu.2015.3881 
81. Dambinova SA. Neurodegradomics: the source of biomarkers for mild 
TBI. In: Dambinova SA, Hayes RL, Wang KKW, editors. Biomarkers for 
TBI. London, UK: RSC Publishing, RSC Drug Discovery Series (2012). 
p. 66–86.
82. Kiechle K, Bazarian JJ, Merchant-Borna K, Stoecklein V, Rozen E, Blyth B, 
et al. Subject-specific increases in serum S-100B distinguish sports-related 
concussion from sports-related exertion. PLoS One (2014) 9:e84977. 
doi:10.1371/journal.pone.0084977 
83. Shahim P, Tegner Y, Wilson DH, Randall J, Skillbäck T, Pazooki D, et al. Blood 
biomarkers for brain injury in concussed professional ice hockey players. 
JAMA Neurol (2014) 71:684–92. doi:10.1001/jamaneurol.2014.367 
84. Posti JP, Takala RS, Runtti H, Newcombe VF, Outtrim J, Katila AJ, et al. The 
levels of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 
during the first week after a traumatic brain injury: correlations with 
clinical and imaging findings. Neurosurgery (2016) 79:456–64. doi:10.1227/
NEU.0000000000001226 
85. Takala RS, Posti JP, Runtti H, Newcombe VF, Outtrim J, Katila AJ, et al. Glial 
fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 as outcome 
predictors in traumatic brain injury. World Neurosurg (2016) 87:8–20. 
doi:10.1016/j.wneu.2015.10.066 
86. Dambinova SA, Shikuev AV, Weissman JD, Mullins JD. AMPAR peptide 
values in blood of nonathletes and club sport athletes with concussions. Mil 
Med (2013) 3:285–90. doi:10.7205/MILMED-D-12-00368 
87. Hammond JC, McCullumsmith RE, Funk AJ, Haroutunian V, Meador-
Woodruff JH. Evidence for abnormal forward trafficking of AMPA 
receptors in frontal cortex of elderly patients with schizophrenia. 
Neuropsychopharmacology (2010) 35:2110–9. doi:10.1038/npp.2010.87 
88. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et  al. AMPA 
receptor antibodies in limbic encephalitis alter synaptic receptor location. 
Ann Neurol (2009) 65:424–34. doi:10.1002/ana.21589 
89. Shrey DW, Griesbach GS, Giza CC. The pathophysiology of concussions 
in youth. Phys Med Rehabil Clin N Am (2011) 22:577–602. doi:10.1016/ 
j.pmr.2011.08.002 
90. Sharp CD, Fowler M, Jackson TH, Houghton J, Warren A, Nanda A, et al. 
Human neuroepithelial cells express NMDA receptors. BMC Neurosci (2003) 
4:28. doi:10.1186/1471-2202-4-28 
91. Danilenko UD, Khunteev GA, Bagumyan A, Izykenova GA. Neurotoxicity 
biomarkers in experimental acute and chronic brain injury. In: Dambinova 
SA, Hayes RL, Wang KKW, editors. Biomarkers for TBI. London, UK: RSC 
Publishing, RSC Drug Discovery Series (2012). p. 87–98.
92. Jin XT, Smith Y. Localization and functions of kainate receptors in the basal 
ganglia. In: Rodriguez-Moreno A, Sihra TS, editors. Kainate Receptors. New 
York: Springer (2011). p. 27–37.
93. Alexandrova EV, Zaitsev OS, Potapov AA. Neurotransmitter basis of con-
sciousness and unconsciousness states. Zh Vopr Neirokhir Im NN Burdenko 
(2014) 78:26–32. 
94. Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, et al. Validation of 
serum markers for blood-brain barrier disruption in traumatic brain injury. 
J Neurotrauma (2009) 26:1497–507. doi:10.1089/neu.2008-0738 
95. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking 
to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 
(2005) 26:485–95. doi:10.1016/j.it.2005.07.004 
96. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with 
diseases of the CNS: new developments and future challenges. Lancet Neurol 
(2011) 10:759–72. doi:10.1016/S1474-4422(11)70096-5 
97. Raad M, Nohra E, Chams N, Itani M, Talih F, Mondello S, et al. Autoantibodies 
in traumatic brain injury and central nervous system trauma. Neuroscience 
(2014) 281:16–23. doi:10.1016/j.neuroscience.2014.08.045 
98. Blaylock RL, Maroon JC. Imminoexcitotoxicity as a central mechanism in 
chronic traumatic encephalopathy – A unifying hypothesis. In: Dambinova 
SA, Hayes RL, Wang KKW, editors. Biomarkers for TBI. London, UK: RSC 
Publishing, RSC Drug Discovery Series (2012). p. 45–65.
99. Weissman JD, Khunteev GA, Heath R, Dambinova SA. NR2 antibodies: 
risk assessment of transient ischemic attack (TIA)/stroke in patients with 
history of isolated and multiple cerebrovascular events. J Neurol Sci (2011) 
300:97–102. doi:10.1016/j.jns.2010.09.023 
100. Nasser M, Bejjani F, Raad M, El Hassan HA, Mantash S, Nokkari A, et al. 
Traumatic brain injury and blood brain barrier cross talk. CNS Neurol Disord 
Drug Targets (2016) 15:1. doi:10.2174/1871527315666160815093525 
101. Dambinova SA. Biomarkers for transient ischemic attack (TIA) and ischemic 
stroke. Clin Lab Int (2008) 32:7–11. 
102. Dambinova SA, Izykenova GA, Burov SV, Grigorenko EV, Gromov SA. 
The presence of autoantibodies to N-terminus domain of GluR1 subunit of 
AMPA receptor in the blood serum of patients with epilepsy. J Neurol Sci 
(1997) 152:93–7. doi:10.1016/S0022-510X(97)00150-0 
103. Dambinova SA, Granstrem OK, Tourov A, Salluzzo R, Castello F, 
Izykenova GA. Monitoring of brain spiking activity and autoantibodies to 
N-terminus domain of GluR1 subunit of AMPA receptors in blood serum 
of rats with cobalt-induced epilepsy. J Neurochem (1998) 71:2088–93. 
doi:10.1046/j.1471-4159.1998.71052088.x 
104. Goryunova AV, Bazarnaya NA, Sorokina EG, Semenova NY, Globa OV, 
Semenova ZhB, et al. Glutamate receptor antibody concentrations in chil-
dren with chronic post-traumatic headache. Neurosci Behav Physiol (2007) 
37:761–4. doi:10.1007/s11055-007-0079-3 
105. Mullins JD, Shikuev AV, Danilenko UI, Dambinova SA. AMPAR Peptide 
values in sport-related concussions. In: 2012 Military Health System Research 
Symposium; 2012 Aug 13-16. Ft. Lauderdale: USAMRMC (2012). p. 134.
106. Mullins JD. Biomarkers of TBI: implications for diagnosis and management 
of contusions. AMSUS 118th Annual Continuing Education Meeting; 2013 
Nov 3-8. Seattle, WA (2013). 147 p. Available from: http://amsusce.org/
wp-content/uploads/2015/05/Abstract-Summaries-10.22.13.2.pdf
107. Sorokina EG, Semenova ZhB, Bazarnaya NA, Meshcheryakov SV, Reutov VP, 
Goryunova AV, et al. Autoantibodies to glutamate receptors and products of 
nitric oxide metabolism in serum in children in the acute phase of cranioce-
rebral trauma. Neurosci Behav Physiol (2009) 39:329–34. doi:10.1007/
s11055-009-9147-1 
108. Dambinova SA, Gill S, St. Onge L, Sowell RL. Biomarkers for subtle brain dys-
function. In: Dambinova SA, Hayes RL, Wang KKW, editors. Biomarkers for TBI. 
London, UK: RSC Publishing, RSC Drug Discovery Series (2012). p. 134–47.
109. Nag S, Kapadia A, Stewart DJ. Review: molecular pathogenesis of blood-
brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol 
(2011) 37:3–23. doi:10.1111/j.1365-2990.2010.01138.x 
110. Siman R, Giovannone N, Hanten G, Wilde EA, McCauley SR, Hunter JV, et al. 
Evidence that the blood biomarker SNTF predicts brain imaging changes and 
persistent cognitive dysfunction in mild TBI patients. Front Neurol (2013) 
4:190. doi:10.3389/fneur.2013.00190 
111. Berger RP, Hayes RL, Richichi R, Beers SR, Wang KK. Serum concentrations 
of ubiquitin C-terminal hydrolase-L1 and αII-spectrin breakdown product 
145 kDa correlate with outcome after pediatric TBI. J Neurotrauma (2012) 
29:162–7. doi:10.1089/neu.2011 
112. Koh SX, Lee JK. S100B as a marker for brain damage and blood-brain barrier 
disruption following exercise. Sports Med (2014) 44:369–85. doi:10.1007/
s40279-013-0119-9 
113. Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, et al. Elevated 
levels of serum glial fibrillary acidic protein breakdown products in mild and 
moderate traumatic brain injury are associated with intracranial lesions and 
neurosurgical intervention. Ann Emerg Med (2012) 59:471–83. doi:10.1016/j.
annemergmed.2011.08.021 
114. Jaber Z, Aouad P, Al Medawar M, Bahmad H, Abou-Abbass H, Ghandour 
H, et  al. Role of systems biology in brain injury biomarker discovery: 
12
Dambinova et al. Integrative Assessment of Concussions
Frontiers in Neurology | www.frontiersin.org October 2016 | Volume 7 | Article 172
neuroproteomics application. In: Kobeissy F, Dixon CE, Hayes RL, Mondello 
S, editors. Injury Models of the Central Nervous System (Vol. 1462). New York: 
Humana Press, Methods Mol Biol Series (2016). p. 157–74.
115. Sedaghat F, Notopoulos A. S100 protein family and its application in clinical 
practice. Hippokratia (2008) 12:198–204. 
116. Steiner J, Bernstein H-G, Bielau H, Berndt A, Brisch R, Mawrin C, et  al. 
Evidence for a wide extra-astrocytic distribution of S100B in human brain. 
BMC Neurosci (2007) 8:2. doi:10.1186/1471-2202-8-2 
117. Puvenna V, Brennan C, Shaw G, Yang C, Marchi N, Bazarian JJ, et  al. 
Significance of ubiquitin carboxy-terminal hydrolase L1 elevations in ath-
letes after sub-concussive head hits. PLoS One (2014) 9:e96296. doi:10.1371/
journal.pone.0096296 
118. Zongo D, Ribereau-Gayon R, Masson F, Laborey M, Contrand B, 
Salmi LR, et al. S100-B protein as a screening tool for the early assessment 
of minor head injury. Ann Emerg Med (2012) 59:209–18. doi:10.1016/ 
j.annemergmed.2011.07.027 
119. Dorminy M, Hoogeveen A, Tierney RT, Higgins M, McDevitt JK, 
Kretzschmar J. Effect of soccer heading ball speed on S100B, sideline concus-
sion assessments and head impact kinematics. Brain Inj (2015) 29:1158–64. 
doi:10.3109/02699052.2015.1035324 
120. Hansen-Schwartz J, Bouchelouche PN. Use of biomarker S100B for traumatic 
brain damage in the emergency department may change observation strategy. 
Dan Med J (2014) 61:A4894. 
121. Laribi S, Kansao J, Borderie D, Collet C, Deschamps P, Ababsa R, et  al. 
S100B blood level measurement to exclude cerebral lesions after minor head 
injury: the multicenter STIC-S100 French study. Clin Chem Lab Med (2014) 
52:527–36. doi:10.1515/cclm-2013-0621 
122. Bazarian JJ, Blyth BJ, He H, Mookerjee S, Jones C, Kiechle K, et al. Classification 
accuracy of serum Apo A-I and S100B for the diagnosis of mild traumatic 
brain injury and prediction of abnormal initial head computed tomography 
scan. J Neurotrauma (2013) 30:1747–54. doi:10.1089/neu.2013.2853 
123. Bazarian JJ, Zhu T, Zhong J, Janigro D, Rozen E, Roberts A, et al. Persistent, 
long-term cerebral white matter changes after sports-related repetitive 
head impacts. PLoS One (2014) 9:e94734. doi:10.1371/journal.pone. 
0094734 
124. Metting Z, Wilczak N, Rodiger LA, Schaaf JM, van der Naalt J. GFAP and 
S100B in the acute phase of mild traumatic brain injury. Neurology (2012) 
78:1428–33. doi:10.1212/WNL.0b013e318253d5c7 
125. McMahon PJ, Panczykowski DM, Yue JK, Puccio AM, Inoue T, Sorani MD, 
et  al. Measurement of the glial fibrillary acidic protein and its breakdown 
products GFAP-BDP biomarker for the detection of traumatic brain injury 
compared to computed tomography and magnetic resonance imaging. 
J Neurotrauma (2015) 32:527–33. doi:10.1089/neu.2014.3635 
126. Papa L, Silvestri S, Brophy GM, Giordano P, Falk JL, Braga CF, et al. GFAP 
out-performs S100β in detecting traumatic intracranial lesions on computed 
tomography in trauma patients with mild traumatic brain injury and those 
with extracranial lesions. J Neurotrauma (2014) 31:1815–22. doi:10.1089/
neu.2013.3245 
127. Mondello S, Linnet A, Buki A, Robicsek S, Gabrielli A, Tepas J, et al. Clinical 
utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for 
severe traumatic brain injury. Neurosurgery (2012) 70:666–75. doi:10.1227/
NEU.0b013e318236a809 
128. Mondello S, Kobeissy F, Vestri A, Hayes RL, Kochanek PM, Berger RP. Serum 
concentrations of ubiquitin C-terminal hydrolase-L1 and glial fibrillary 
acidic protein after pediatric traumatic brain injury. Sci Rep (2016) 6:28203. 
doi:10.1038/srep28203 
129. Mondello S, Palmio J, Streeter J, Hayes RL, Peltola J, Jeromin A. Ubiquitin 
carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid 
and plasma of patients after epileptic seizure. BMC Neurol (2012) 12:85. 
doi:10.1186/1471-2377-12-85 
130. McKee AC, Stein TD, Kiernan PT, Alvarez VE. The neuropathology of chronic 
traumatic encephalopathy. Brain Pathol (2015) 25:350–64. doi:10.1111/
bpa.12248 
131. Solomon GS, Zuckerman SL. Chronic traumatic encephalopathy in 
professional sports: retrospective and prospective views. Brain Inj (2015) 
29:164–70. doi:10.3109/02699052.2014.965205 
132. Omalu B, Hammers JL, Bailes J, Hamilton RL, Kamboh MI, Webster G, et al. 
Chronic traumatic encephalopathy in an Iraqi war veteran with posttrau-
matic stress disorder who committed suicide. Neurosurg Focus (2011) 31:E3. 
doi:10.3171/2011.9.FOCUS11178 
133. Gandy S, Ikonomovic MD, Mitsis E, Elder G, Ahlers ST, Barth J, et  al. 
Chronic traumatic encephalopathy: clinical-biomarker correlations 
and current concepts in pathogenesis. Mol Neurodegener (2014) 9:37. 
doi:10.1186/1750-1326-9-37 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Dambinova, Maroon, Sufrinko, Mullins, Alexandrova and 
Potapov. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
